Network Pharmacology and Mechanism Studies of the Protective Effect of Ginseng against Alzheimerʼs Disease Based on Aβ Pathogenesis
Planta Medica · 01.08.2023 · 89 (10) · 990-1000
DOI: 10.1055/a-2014-6061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.08.2023. Verfasst von Jinman Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Jiangmen TCM Hospital of Ji'nan University, Jiangmen, China. Hauptthemen laut MEDLINE: Panax, Alzheimer Disease, Ginsenosides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Key laboratory project of colleges and universities in Guangdong province, science and technology program of Guangzhou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Alzheimerʼs disease (AD) is a critical neurodegenerative disease that manifests as progressive intellectual decline and is pathologically characterized by a progressive loss of neurons in the brain. Despite extensive research on this topic, the pathogenesis of AD is not fully understood, while the beta-amyloid (Aβ) hypothesis remains the dominant one and only a few symptomatic drugs are approved for the treatment of AD. Ginseng has been widely reported as an effective herbal medicine for the treatment of neurodegenerative diseases such as dementia. Therefore, we explore the protective effects of ginseng in AD by a network pharmacological approach based on the pathogenesis of Aβ. Twenty-one major ginsenosides are screened based on ultraperformance liquid chromatography-mass spectrometry/mass spectrometry (HPLC-MS/MS) data. Among them, MAPK8, MAPK9, BACE1, FLT1, CDK2, and CCR5 are the core targets. By molecular docking and validation with the in vitro cell model APPswe-SH-SY5Y, we find that ginsenosides Rg3 and Ro have good neuroprotective effects and can reduce the expression of Aβ 1 – 42 in APPswe-SH-SY5Y. Finally, through RT-qPCR experiment, we find that ginsenoside Rg3 targeted MAPK8, FLT1, and CCR5, while ginsenoside Ro targeted MAPK8, MAPK9, FLT1, and CCR5 for its potential anti-AD efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Affiliated Jiangmen TCM Hospital of Ji'nan University, Jiangmen, China.
- Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
ORCID-Profile: Jinman Liu
Förderung
- Key laboratory project of colleges and universities in Guangdong province
- science and technology program of Guangzhou
- National Natural Science Foundation of China
- Guangdong province science and technology plan international cooperation project
Zitieren
APA
Liu, J., Yu, W., Ma, C., Li, T., Liang, Y., Su, S., Zhong, G., Xie, Z., Wu, Q., Chen, J., & Wang, Q. (2023). Network Pharmacology and Mechanism Studies of the Protective Effect of Ginseng against Alzheimerʼs Disease Based on Aβ Pathogenesis. Planta Medica, 89(10), 990-1000. https://doi.org/10.1055/a-2014-6061
Vancouver
Liu J, Yu W, Ma C, Li T, Liang Y, Su S, et al. Network Pharmacology and Mechanism Studies of the Protective Effect of Ginseng against Alzheimerʼs Disease Based on Aβ Pathogenesis. Planta Medica. 2023;89(10):990-1000. doi:10.1055/a-2014-6061
BibTeX
@article{Liu2023,
author = {Liu, Jinman and Yu, Wenqian and Ma, Cuiru and Li, Tianyao and Liang, Yong and Su, Shijie and Zhong, Guangcheng and Xie, Zhouyuan and Wu, Qiqing and Chen, Jiaxin and Wang, Qi},
title = {Network Pharmacology and Mechanism Studies of the Protective Effect of Ginseng against Alzheimerʼs Disease Based on Aβ Pathogenesis},
journal = {Planta Medica},
year = {2023},
volume = {89},
number = {10},
pages = {990--1000},
doi = {10.1055/a-2014-6061}
}
EUVIMED